Magrolimab (Hu5F9-G4) is a first-in-class humanized anti-CD47 IgG4 antibody with an anti-tumor activity[1].
[1]. Caner Saygin, et al. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 1mg | ¥2,070.00 | 现货 | 1 | |
| 5mg | ¥4,950.00 | 现货 | 1 | |
| 10mg | ¥7,200.00 | 现货 | 1 |
















Magrolimab (Hu5F9-G4) is a first-in-class humanized anti-CD47 IgG4 antibody with an anti-tumor activity[1].
[1]. Caner Saygin, et al. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.